Followers | 37 |
Posts | 4190 |
Boards Moderated | 0 |
Alias Born | 10/18/2016 |
Friday, January 26, 2018 12:44:14 PM
- Included are drugs formulated to treat Alzheimer’s, Parkinson’s, eating disorders and seizures
- IGC already has seven provisional filings for phytocannabinoid-based combination therapies
- Company also has in its pipeline combination therapy drug candidates for the treatment of end points of Parkinson’s, as well as epilepsy in cats and dogs
India Globalization Capital, Inc. (NYSE American: IGC) anticipates filing, in 2018 and 2019, for international Patent Cooperation Treaty (“PCT”) patents, as well as U.S. national patent filings, for a portfolio of drugs (http://nnw.fm/A5Kpn).
Its drug for the treatment of Alzheimer’s (IGC-AD1) is anticipated for patent filings in PCT and the U.S. in 2018. Its seizure drug (IGC-505) is scheduled for filing for a U.S. patent in late 2018. The company’s eating disorders drug (IGC-504) is anticipated for filing for a U.S. patent late this year, while another eating disorders drug (IGC-506) is anticipated for filing for a PCT patent in 2018 and a U.S. filing in 2019. This portfolio encompasses the company’s drugs that are formulated to treat seizures, Alzheimer’s and eating disorders — representing large domestic and international markets.
For its drug formulated to treat Alzheimer’s, as described in a SeeThruEquity update on IGC (http://nnw.fm/Taj4J), it has formulated a cannabis-based combination which treats endpoints of the disease such as plaques, tangles, anxiety and agitation. IGC plans to market its patent-pending drug through U.S. and Canadian medical dispensaries in early 2018. A key goal for the company in 2018 is to get its lead product formulation, Hyalolex, ready for phase IIB human trials. IGC estimates that Alzheimer’s disease costs the U.S. economy alone roughly $236 billion annually. It affects more than 5.3 million Americans, and more than 65 percent of its patients are women.
IGC is a Maryland-based company with two lines of businesses. One is legacy, which includes the rental of heavy equipment, real estate management and commodities trading. The second is canna-pharmaceutical. That business is focused on developing a formulation using cannabis extracts for the treatment of many diseases.
For more information, visit the company’s website at www.IGCInc.us
Recent IGC News
- IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two • Business Wire • 04/16/2024 11:00:00 AM
- IGC Pharma Adds Advisor in Artificial Intelligence • Business Wire • 04/09/2024 01:00:00 PM
- IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock • Business Wire • 03/26/2024 07:00:00 PM
- IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation • Business Wire • 03/20/2024 03:00:00 PM
- IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024 • Business Wire • 03/20/2024 11:00:00 AM
- IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline • Business Wire • 03/12/2024 07:00:00 PM
- Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model • Business Wire • 02/28/2024 06:00:00 PM
- IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target • Business Wire • 02/23/2024 05:01:00 PM
- IGC Pharma Reports Third Quarter Fiscal 2024 Results • Business Wire • 02/17/2024 12:05:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:03:00 PM
- IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model • Business Wire • 02/01/2024 02:20:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/31/2024 09:04:23 PM
- IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s • Business Wire • 01/23/2024 02:20:00 PM
- IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s Trial • Business Wire • 01/17/2024 02:20:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/09/2024 05:15:07 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/29/2023 09:54:29 PM
- Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’s • Business Wire • 12/19/2023 02:20:00 PM
- IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024 • Business Wire • 12/13/2023 02:30:00 PM
- IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials • Business Wire • 12/06/2023 01:30:00 PM
- IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives • Business Wire • 11/21/2023 01:30:00 PM
- IGC Pharma Reports Second Quarter Fiscal 2024 Results • Business Wire • 11/13/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:15:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 09:21:48 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/27/2023 08:38:17 PM
- IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy • Business Wire • 10/19/2023 07:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM